Using advanced mass spectrometry-based techniques, it was shown that using a panel of APOA1, APOE, APOL1, and trypsin inhibitor heavy chain H3 (ITIH3) can provide a sensitivity of 95% and specificity of 94.1% in the diagnosis of pancreatic cancer [1]. This evidence concerns the gene APOE and pancreatic neoplasm.